SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that ...
from PR Newswire: https://prn.to/2HRwvh8
No comments:
Post a Comment